Hutch News

Hutch News

Stories tagged 'David M Hockenbery'

Machine learning provides new insights into tumor suppression

Algorithm illuminated surprising metabolic effects of important cancer gene

May 7, 2018 | by Susan Keown / Fred Hutch News Service

A machine learning algorithm helped Fred Hutch scientists solve a challenging problem in cancer genomics. And the surprising answer has revealed potential new targets for cancer drugs.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

March 10, 2016

Drs. Michael Emerman and Nina Salama elected to Fellowship in the American Academy of Microbiology; Dr. William Grady receives grant for esophageal cancer screening study; Dr. Andrew Hsieh earns 2016 ASCI Young Physician-Scientist Award; New interactive map is hub for global breast cancer data

View story >


Center awarded $11.5 million for breast cancer research consortium

Porter, Cheever will lead the five-year Seattle-based SPORE in projects including development of targeted treatments for drug-resistant tumors

Nov. 15, 2010 | By Kristen Woodward

The National Cancer Institute has awarded $11.5 million to the Fred Hutchison Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.

View story >


Pond poison tackles tenacious cancer cells

Modified cell toxin used to control invasive fish populations may lead to drug that lowers resistance to cancer therapies

Aug. 1, 2007 | By DEAN FORBES

View story >


Gaining gastrointestinal GVHD control

Phase III clinical trial on drug therapy to combat graft-vs.-host disease in stem-cell patients shows significant reduction in deaths

Jan. 29, 2007 | By DEAN FORBES

Hutchinson Center researchers have developed a new drug therapy that significantly reduces death from gastrointestinal graft-vs.-host disease in allogeneic stem-cell transplant patients. By adding a widely used topical corticosteroid to the standard GVHD treatment, researchers found it kept the potentially deadly side effect in remission and reduced death by 46 percent one year after therapy.

View story >


PHS investigator Ramsey chosen for ASCI

April 6, 2006

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.